We came across a bullish thesis on Eli Lilly and Company (LLY ... which is set to expand into new therapeutic areas. Despite increasing competition, the company remains strong in both the U.S ...

We came across a bullish thesis on Eli Lilly and Company (LLY ... which is set to expand into new therapeutic areas. Despite increasing competition, the company remains strong in both the ...

In Q4 2024, Eli Lilly’s top-performing drugs included Mounjaro, which saw a 60% increase in revenue, and Zepbound, which is set to expand into new therapeutic areas. Despite increasing competition, ...

(see more details here). Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical powerhouse renowned for pioneering advancements in therapeutic areas such as diabetes, oncology, neuroscience ...

The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, ...

obesity and future pipeline medicines across therapeutic areas. Lilly expects to add 750 highly skilled jobs to the current 100-plus workforce at this location. Eli Lilly and Company (NYSE ...

Major stock indexes closed higher on Friday, driven by corporate earnings reports from tech firms like Alphabet and Amazon.

Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a cancer drug from Scorpion Therapeutics Inc. The pharmaceutical company ...

Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Ibex Prostate Detect, an ...

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

(Bloomberg) -- Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a cancer drug from Scorpion Therapeutics Inc. The ...

Organon (NYSE: OGN) today announced its results for the fourth quarter and full year ended December 31, 2024. “In 2024 we achieved our third year of constant currency revenue growth and delivered ...